ClinicalTrials.gg
CompletedNCT03218917Updated Mar 27, 2023Results posted

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

A Phase 2 interventional study of Brensocatib 10 mg and Brensocatib 25 mg in Non-Cystic Fibrosis Bronchiectasis, sponsored by Insmed Incorporated. Completed at 108 sites in 14 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Enrollment
19th of 52
256 · median 78
Started
2017
with 1 other
Phase 2
15 of 65
4 open now
Registered
27th of 65
by date
Lead sponsor
3 of 65
Insmed Incorporated

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 19th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2017, is one of 15 in phase 2, and was the 27th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.

Read the detailed description

Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter, multi-national study to assess the efficacy, safety and tolerability, and pharmacokinetics (PK) of INS1007 administered once daily for 24 weeks in participants with non-cystic fibrosis bronchiectasis (NCFBE).

03

Conditions studied

  • Non-Cystic Fibrosis Bronchiectasis

Browse trials for

Keywords

  • P aeruginosa
  • bronchiectasis
  • active neutrophil elastase
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical history consistent with NCFBE (cough, chronic sputum production and/or recurrent respiratory infections)
  2. Are current sputum producers with a history of chronic expectoration and able to provide a sputum sample during Screening
  3. Have at least 2 documented pulmonary exacerbations in the past 12 months before Screening

Exclusion criteria

Exclusion Criteria:

  1. Have a primary diagnosis of (COPD) or asthma
  2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common variable immunodeficiency, or alpha1-antitrypsin deficiency
  3. Are current smokers
  4. Are currently being treated for a nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis
  5. Have any acute infections, (including respiratory infections)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Brensocatib 10 mg

    Participants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.

    Drug: Brensocatib 10 mg

  • Experimental
    Brensocatib 25 mg

    Participants received brensocatib 25 mg QD before breakfast, for 24 weeks.

    Drug: Brensocatib 25 mg

  • Placebo comparator
    Placebo

    Participants received the matching placebo QD before breakfast, for 24 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period

    Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation. The analysis was performed using the stratified log rank test and using Kaplan Meier (KM) curves.

    Time frame: Baseline (Day 1) to Week 24

Secondary outcomes

  1. Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period

    The QOL-B is a validated, self-administered patient reported outcome (PRO) that assesses symptoms, functioning, and health-related (HR) QOL for participants with non-cystic fibrosis bronchiectasis (NCFBE). The QOL-B contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HR QoL. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. The analysis was based on mixed model for repeated measures (MMRM) approach.

    Time frame: Baseline (Day 1) to Week 24

  2. Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period

    FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after taking a deep breath. The percent predicted FEV1 was calculated by converting the spirometer reading to a percentage of what would be predicted as normal FEV1 based on a several personal factors (e.g. sex, age, etc.). Change from screening in percent predicted FEV1 to Week 24 was calculated as: percent predicted FEV1 value at Week 24 and percent predicted FEV1 value at screening. A positive percent change from screening indicates an improvement in lung function. The analysis was done using analysis of covariance (ANCOVA) with Pa colonization status and maintenance macrolide antibiotic use at Baseline as covariates.

    Time frame: Screening (Days -42 to -1) to Week 24

  3. Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum

    The concentration of active NE in sputum, was measured by the difference between the pre-treatment concentration and on-treatment concentration. In bronchiectasis, activation of neutrophils in the airway leads to release of NE which leads to damaged airway walls, mucus hypersecretion, exacerbated inflammation, which in turn affects neutrophil and macrophage functions, increasing the risk of infection. Negative change from Baseline indicates improvement.

    Time frame: Baseline (Day 1) to Week 24

  4. Number of Participants Who Experienced a Pulmonary Exacerbation

    Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics. 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation.

    Time frame: Baseline (Day 1) to Week 24

07

Results

Posted Feb 8, 2023

Participant flow

Participants took part in the trial at 116 sites in 14 countries from 31 October 2017 to 12 December 2019.

Participant flow — Overall Study
MilestoneBrensocatib 10 mgBrensocatib 25 mgPlacebo
Started828787
Received study treatment (safety population)818985
Participants did not receive drug001
Pharmacodynamic (pd) population808984
Completed767574
Not completed61213
Withdrew: Adverse event332
Withdrew: Subject withdrew consent2410
Withdrew: Physician decision011
Withdrew: Lost to follow-up100
Withdrew: Reason missing020
Withdrew: Death010
Withdrew: Non-compliance with study drug010

Outcome measures

PrimaryTime to the First Pulmonary Exacerbation Over 24-Week Treatment Period

Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation. The analysis was performed using the stratified log rank test and using Kaplan Meier (KM) curves.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Median · days
Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period
daysBrensocatib 10 mgBrensocatib 25 mgPlacebo
Time to the First Pulmonary Exacerbation Over 24-Week Treatment PeriodNA (NA to NA)NA (NA to NA)189.0 (141.0 to NA)
Statistical analysis
  • Brensocatib 10 mg · Stratified Log-rank test · p = = 0.014 (P-value is one-sided for superiority.)Stratified by Pseudomonas aeruginosa (Pa) colonization status and maintenance antibiotic use at Baseline.
  • Brensocatib 25 mg vs Placebo · Stratified Log-rank test · p = = 0.022 (P-value is one-sided for superiority.)Stratified by colonization status and maintenance antibiotic use at Baseline.
SecondaryChange From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period

The QOL-B is a validated, self-administered patient reported outcome (PRO) that assesses symptoms, functioning, and health-related (HR) QOL for participants with non-cystic fibrosis bronchiectasis (NCFBE). The QOL-B contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HR QoL. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. The analysis was based on mixed model for repeated measures (MMRM) approach.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period
score on a scaleBrensocatib 10 mgBrensocatib 25 mgPlacebo
Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period3.8 ± 0.785.9 ± 0.765.7 ± 0.77
SecondaryChange From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period

FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after taking a deep breath. The percent predicted FEV1 was calculated by converting the spirometer reading to a percentage of what would be predicted as normal FEV1 based on a several personal factors (e.g. sex, age, etc.). Change from screening in percent predicted FEV1 to Week 24 was calculated as: percent predicted FEV1 value at Week 24 and percent predicted FEV1 value at screening. A positive percent change from screening indicates an improvement in lung function. The analysis was done using analysis of covariance (ANCOVA) with Pa colonization status and maintenance macrolide antibiotic use at Baseline as covariates.

Time frame:
Screening (Days -42 to -1) to Week 24
Reported as:
Least squares mean · percent predicted FEV1
Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period
percent predicted FEV1Brensocatib 10 mgBrensocatib 25 mgPlacebo
Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period-0.3 ± 0.88-0.3 ± 0.85-1.8 ± 0.87
SecondaryChange From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum

The concentration of active NE in sputum, was measured by the difference between the pre-treatment concentration and on-treatment concentration. In bronchiectasis, activation of neutrophils in the airway leads to release of NE which leads to damaged airway walls, mucus hypersecretion, exacerbated inflammation, which in turn affects neutrophil and macrophage functions, increasing the risk of infection. Negative change from Baseline indicates improvement.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Least squares mean · microgram/ milliliter (µg/mL)
Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum
microgram/ milliliter (µg/mL)Brensocatib 10 mgBrensocatib 25 mgPlacebo
Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum-2.928 ± 0.351-4.117 ± 0.322-1.409 ± 0.313
SecondaryNumber of Participants Who Experienced a Pulmonary Exacerbation

Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics. 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Pulmonary Exacerbation
ParticipantsBrensocatib 10 mgBrensocatib 25 mgPlacebo
Number of Participants Who Experienced a Pulmonary Exacerbation262942

Adverse events

Collected over Baseline to Week 28 (End of study visit). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brensocatib 10 mg0/81 (0%)11/81 (13.6%)47/81 (58%)
Brensocatib 25 mg1/89 (1.1%)10/89 (11.2%)43/89 (48.3%)
Placebo0/85 (0%)19/85 (22.4%)33/85 (38.8%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventBrensocatib 10 mgBrensocatib 25 mgPlacebo
Infective exacerbation of bronchiectasisInfections and infestations5/814/899/85
PneumoniaInfections and infestations0/814/893/85
HaemoptysisRespiratory, thoracic and mediastinal disorders0/810/892/85
BronchitisInfections and infestations1/810/890/85
AspergillomaInfections and infestations1/810/890/85
Subcutaneous abscessInfections and infestations1/810/890/85
Carotid artery occlusionNervous system disorders1/810/890/85
Carotid artery stenosisNervous system disorders1/810/890/85
Transient ischaemic attackNervous system disorders1/810/891/85
LymphocytosisBlood and lymphatic system disorders1/810/890/85
Most frequent other events
Showing 10 of 12
Most frequent other events
EventBrensocatib 10 mgBrensocatib 25 mgPlacebo
CoughRespiratory, thoracic and mediastinal disorders15/8112/8910/85
HeadacheNervous system disorders8/8112/893/85
Sputum increasedRespiratory, thoracic and mediastinal disorders9/819/896/85
DiarrhoeaGastrointestinal disorders5/813/899/85
DyspnoeaRespiratory, thoracic and mediastinal disorders3/818/892/85
FatigueGeneral disorders3/817/896/85
Upper respiratory tract infectionInfections and infestations6/814/894/85
ArthralgiaMusculoskeletal and connective tissue disorders6/811/891/85
HaemoptysisRespiratory, thoracic and mediastinal disorders6/812/891/85
SinusitisInfections and infestations5/814/896/85

Baseline characteristics

ITT population included all the participants who were randomized.

Age, Continuous
Age, Continuous(years)Brensocatib 10 mgBrensocatib 25 mgPlaceboTotal
Mean64.6 ± 12.4263.7 ± 12.6764.0 ± 11.8664.1 ± 12.27
Sex: Female, Male
Sex: Female, Male(Participants)Brensocatib 10 mgBrensocatib 25 mgPlaceboTotal
Female576255174
Male25253282
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brensocatib 10 mgBrensocatib 25 mgPlaceboTotal
Hispanic or Latino2406
Not Hispanic or Latino808387250
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brensocatib 10 mgBrensocatib 25 mgPlaceboTotal
Race — Caucasian (White)767871225
Race — African American/Black of African origin0224
Race — Asian551323
Race — American Indian or Alaska Native0000
Race — Native Hawaiian or Other Pacific Islander1113
Race — Other0101
08

Study locations

108 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Phoenix Medical Group
    Peoria, Arizona 85381, United States
  • NewportNativeMD
    Newport Beach, California 92663, United States
  • Palmtree Clinical Research
    Palm Springs, California 92262-4871, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • Stanford University Medical Center
    Stanford, California 94305-5236, United States
  • National Jewish Heath
    Denver, Colorado 80206, United States
  • UConn Health Center
    Farmington, Connecticut 06030-1321, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Clinical Research Specialists, LLC
    Celebration, Florida 34747, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Sarasota Memorial Hospital Clinical Research Center
    Sarasota, Florida 34239, United States
  • The Emory Clinic, Pulmonology
    Atlanta, Georgia 30342-2147, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • LSU Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins University, Division of Pulmonary and Critical Care Medicine
    Baltimore, Maryland 21205, United States
  • Pulmonary and Critical Care Associates of Baltimore
    Towson, Maryland 21286, United States
  • Mid Atlantic Pulmonary & Research Center
    Westminster, Maryland 21157, United States
  • Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • NYU Pulmonary & Critical Care Associates
    New York, New York 10016, United States
  • Columbia University Medical Center/ New York Presbyterian Hospital
    New York, New York 10032, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Novant Health Pulmonary Medicine South
    Charlotte, North Carolina 28215, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • SMS Clinical Research, LLC
    Mesquite, Texas 75149, United States
  • The University of Texas Health Science at Tyler
    Tyler, Texas 75708, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Mater Misericordia Medical Centre
    Brisbane, Queensland 4101, Australia
  • Gallipoli Medical Research Foundation
    Brisbane, Queensland 4120, Australia
  • Metro North Hospital and Health Service (The Prince Charles Hospital)
    Chermside, Queensland 4032, Australia
  • Respiratory Clinical Trials Unit, Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Respiratory Clinical Trials PTY LTD
    Kent Town, South Australia 5067, Australia
  • Box Hill Hospital, Eastern Clinical Research Unit
    Box Hill, Victoria 3128, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Institute for Respiratory Health
    Nedlands, Western Australia 6009, Australia
  • UZ Leuven
    Leuven, Vlaams Brabant 3000, Belgium
  • Medical Center ReSpiro Ltd (Kiselov)
    Razgrad, Momina 7200, Bulgaria
  • Medical Center UNIMED
    Plovdiv, 4000, Bulgaria
  • MHAT "Dr IvanSeliminski"-Sliven
    Sliven, 8800, Bulgaria
  • Cardioart Medical Center
    Stara Zagora, 6000, Bulgaria
  • Hvidovre Hospital
    Hvidovre, Capital Region 2650, Denmark
  • Aarhus University Hospital
    Aarhus, 8000, Denmark
  • Sjællands Universitetshospital, Roskilde
    Roskilde, 4000, Denmark
  • Krankenhaus Donaustauf
    Donaustauf, Bavaria 93093, Germany
  • Klinikum der Universität München Medizinische Klinik V Pneumologie / Mukoviszidose-Zentrum für Erwachsene
    Munich, Bavaria 80336, Germany
  • Klinikum Nuernberg
    Nuernberg, Bayern 90419, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt, Hessen 60590, Germany
  • IKF Pneumologie Frankfurt
    Frankfurt, Hessen 60596, Germany
  • Ruhrlandklinik Essen, University Essen
    Essen, NRW 45239, Germany
  • Forschungszentrum Borstel
    Borstel, Schleswig-Holstein 23845, Germany
  • Universitätsklinikum Jena
    Jena, Thuringen 7747, Germany
  • Research Center for Medical Studies (RCMS)
    Berlin, 10717, Germany
  • Städt. Klinikum München GmbH, Bogenhausen
    München, 81925, Germany
  • University of Milan, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico
    Milan, Lombardia 20122, Italy
  • Ospedale San Gerardo
    Monza, Monza E Brianza 20900, Italy
  • University Hospital of Pisa
    Pisa, Via Paradisa 2 56124, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • ICS Maugeri spa SB, IRCSS Telese
    Telese Terme, 82037, Italy
  • Inha University Hospital
    Incheon, Jung-gu 22332, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, Namdong-gu 21565, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • The Catholic University of Korea Incheon St. Mary's Hospital
    Incheon, 21431, Korea, Republic of
  • The Catholic University of Korea, St. Paul's Hospital
    Seoul, 02559, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Konkuk University Medical Center
    Seoul, 05030, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Noordwest Ziekenhuis Group
    Alkmaar, 1815JD, Netherlands
  • Amphia Longresearch Astma/COPD Uni 52/5e etage
    Breda, 4818CK, Netherlands
  • RadboudUMC, location Dekkerswald
    Nijmegen, 6525GA, Netherlands
  • Zuyderland MC
    Sittard, 6162BG, Netherlands
  • P3 Research
    Tauranga, BOP 3110, New Zealand
  • P3 Research (Hawke's Bay)
    Hastings, Hawkes Bay 4130, New Zealand
  • Southern District health Board/Dunedin Hospital
    Dunedin, Otago 9016, New Zealand
  • Waikato District Health Board
    Hamilton, Waikato 3204, New Zealand
  • Auckland District Health Board, Greenlane clinical Centre
    Auckland, 1051, New Zealand
  • Centrum Badan Klinicznych, Piotr Napora Lekarze i Spolka Partnerska, Osrodek Badan Wczesnej Fazy
    Wrocław, Dolnośląskie 51-162, Poland
  • Grażyna Jasieniak Pinis Niepubliczny Zakład Opieki Zdrowotnej Atopia
    Kraków, 31-159, Poland
  • NZOZ Krak-Medyk Sp. z o.o
    Kraków, 31-455, Poland
  • Gabinet Lekarski Pediatryczno-Alergologiczny Zenon Bukowczan
    Sucha Beskidzka, 34-200, Poland
  • Medical University of Lodz Poland
    Łódź, 90-153, Poland
  • Singapore General Hospital
    Singapore, 169856, Singapore
  • Changi General Hospital
    Singapore, 529889, Singapore
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Hospital Universitari de Girona Dr. Josep Trueta
    Girona, 17007, Spain
  • Hospital Universiatrio y politecnico La Fe
    Valencia, 46026, Spain
  • NHS Tayside
    Dundee, Angus DD1 9SY, United Kingdom
  • Papworth Hospital NHS Foundation Trust
    Cambridge, Cambridgeshire CB23 3RE, United Kingdom

Showing the first 100 of 108 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O'Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, Daley CL; WILLOW Investigators. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2020 Nov 26;383(22):2127-2137. doi: 10.1056/NEJMoa2021713. Epub 2020 Sep 7. PubMed 32897034 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2019, 25 months.

Results were first posted in Feb 2023, 3 years 1 month after primary completion. A results delay was requested in Dec 2020.

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2017
First posted
Jul 17, 2017
StartActual
Oct 31, 2017
Primary completionActual
Dec 12, 2019
CompletionActual
Dec 12, 2019
Results delay requested
Dec 11, 2020
Results first posted
Feb 8, 2023
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03218917
Responsible party
Sponsor
First posted
Jul 17, 2017
Start date
Oct 31, 2017
Primary completion
Dec 12, 2019
Completion
Dec 12, 2019
Results posted
Feb 8, 2023
Last update
Mar 27, 2023

Study contacts

Carlos Fernandez, MD
study director · Insmed Incorporated

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brensocatib

Start the discussion